Rare diseases
Investigational molecules
Locations
Study on the Long-Term Safety of Alpelisib for Patients with PIK3CA-Related Overgrowth Spectrum (PROS)
FranceStudy on Alpelisib with Fulvestrant or Letrozole for Patients with Advanced Breast Cancer and PIK3CA Mutation After Previous Treatments
DenmarkStudy on Metformin to Prevent High Blood Sugar in Advanced Breast Cancer Patients with Alpelisib and Endocrine Therapy
SpainStudy on Ribociclib, Alpelisib, and Letrozole for Adults with Advanced Hormone Receptor-Positive Breast Cancer
FranceStudy of alpelisib and olaparib combination compared to chemotherapy in patients with platinum-resistant high-grade serous ovarian cancer without BRCA mutation
FinlandStudy on Alpelisib and Fulvestrant for Men and Postmenopausal Women with Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA Mutation
BelgiumStudy on Brexucabtagene Autoleucel for Adults with Relapsed or Refractory Burkitt Lymphoma
AustriaStudy on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Richter Transformation (RT)
AustriaComparing inavolisib plus fulvestrant versus alpelisib plus fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation
BelgiumStudy on Alpelisib and Fulvestrant or Ribociclib and Fulvestrant for Patients with HR+, HER2- Metastatic Breast Cancer with PIK3CA Mutations
FranceStudy of Alpelisib, Trastuzumab, and Fulvestrant for Patients with PIK3CA Mutated HER2+ Advanced Breast Cancer Previously Treated with Trastuzumab
SpainTell us about your condition – we search every trial in Europe and connect you with the right site.
